New Release: Alpha testing version has been released.

Mitomycin

L01D - Cytotoxic antibiotics and related substances ATC L01DC03 Small molecule approved 1981 Parenteral Topical Prodrug Natural product Black-box warning

Active form: Indolohydroquinone.

JFDA label: Misintu

⚠ Black-Box Warning
  • hematological toxicity — ChEMBL drug_warning (Black Box Warning) | United States
  • nephrotoxicity — ChEMBL drug_warning (Black Box Warning) | United States
  • Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possibl

Mechanism of Action

Inhibitor of DNA — DNA inhibitor

TargetActionGene / class
DNA efficacy INHIBITOR

Indications

Approved

  • Adenocarcinoma — adenocarcinoma
  • Glaucoma — glaucoma
  • Neoplasms — neoplasm

Off-label

  • Anus Neoplasms
  • Appendiceal Neoplasms
  • Biliary Tract Neoplasms
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma in Situ
  • Carcinoma, Hepatocellular
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Carcinoma, Transitional Cell
  • Cholangiocarcinoma
  • Cholangitis, Sclerosing
  • Colorectal Neoplasms
  • Corneal Opacity
  • Esophageal Stenosis
  • Glaucoma, Neovascular
  • Glaucoma, Open-Angle
  • Head and Neck Neoplasms
  • Keratoconus
  • Liver Neoplasms
  • Lung Neoplasms
  • Mesothelioma
  • Nasopharyngeal Carcinoma
  • Pancreatic Neoplasms
  • Pterygium
  • Sarcoma
  • Stomach Neoplasms
  • Urethral Stricture
  • Urinary Bladder Neoplasms
  • Uterine Cervical Neoplasms

Contraindications

Source: openFDA

  • Mitomycin is contraindicated in patients who have demonstrated a hypersensitive or idiosyncratic reaction to it in the past. Mitomycin is contraindicated in patients with thrombocytopenia, coagulation disorder, or an increase in bleeding tendency due to other causes. Absolute

Adverse Reactions

Very Common >10%Common 1–10%Uncommon 0.1–1% Rare 0.01–0.1%Very Rare <0.01%Not Known

Respiratory, thoracic and mediastinal disorders (1)

Very Common Pulmonary oedema

Dosing

Source: openFDA

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Mitomycin for injection should be given intravenously only, using care to avoid extravasation of the compound. If extravasation occurs, cellulitis, ulceration, and slough may result. Each vial contains either mitomycin 5 mg and mannitol 10 mg, mitomycin, 20 mg and mannitol 40 mg or mitomycin 40 mg and mannitol 80 mg. To administer, add Sterile Water for Injection, 10 mL, 40 mL or 80 mL respectively. Shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until solution is obtained. After full hematological recovery (see guide to dosage adjustment) from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m 2 intravenously as a single dose via a functioning intravenous catheter. Because of cumulative myelosuppression, patients should be fully reevaluated after each course of mitomycin, and the dose reduced if the patient has experienced any toxicities. Doses greater than 20 mg/m 2 have not been shown to be more effective, and are more toxic than lower doses. The following schedule is suggested as a guide to dosage adjustment: Nadir After Prior Dose Leukocytes /mm 3 Platelets /mm 3 Percentage of Prior Dose To Be Given >4000 >100,000 100% 3000 to 3999 75,000 to 99,999 100% 2000 to 2999 25,000 to 74,999 70% <2000 <25,000 50% No repeat dosage should be given until leukocyte count has returned to 4000/mm 3 and a platelet count to 100,000/mm 3 . When mitomycin for injection is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly. If the disease continues to progress after two courses of mitomycin for injection, the drug should be stopped since chances of response are minimal. STABILITY Unreconstituted mitomycin stored at room temperature is stable for the lot life indicated on the package. Avoid excessive heat (over 40°C, 104°F). Reconstituted with Sterile Water for Injection to a concentration of 0.5 mg per mL, mitomycin for injection is stable for 14 days refrigerated or 7 days at room temperature. Diluted in various I.V. fluids at room temperature, to a concentration of 20 to 40 micrograms per mL: I.V. Fluid Stability 0.9% Sodium Chloride Injection 12 hours Sodium Lactate Injection 24 hours The combination of mitomycin for injection (5 mg to 15 mg) and heparin (1,000 units to 10,000 units) in 30 mL of 0.9% Sodium Chloride Injection is stable for 48 hours at room temperature. Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published. 1 to 8 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.

Warnings & Precautions

Source: openFDA

Boxed Warning

Mitomycin should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available. Bone marrow suppression, notably thrombocytopenia and leukopenia, which may contribute to overwhelming infections in an already compromised patient, is the most common and severe of the toxic effects of mitomycin (see WARNINGS and ADVERSE REACTIONS sections). Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs, however, most cases occur at doses ≥60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined.

Warnings & Precautions

Patients being treated with mitomycin must be observed carefully and frequently during and after therapy. The use of mitomycin results in a high incidence of bone marrow suppression, particularly thrombocytopenia and leukopenia. Therefore, the following studies should be obtained repeatedly during therapy and for at least eight weeks following therapy: platelet count, white blood cell count, differential, and hemoglobin. The occurrence of a platelet count below 100,000/mm 3 or a WBC below 4,000/mm 3 or a progressive decline in either is an indication to withhold further therapy until blood counts have recovered above these levels. Patients should be advised of the potential toxicity of this drug, particularly bone marrow suppression. Deaths have been reported due to septicemia as a result of leukopenia due to the drug. Patients receiving mitomycin should be observed for evidence of renal toxicity. Mitomycin should not be given to patients with a serum creatinine greater than 1.7 mg percent. Usage in Pregnancy Safe use of mitomycin in pregnant women has not been established. Teratological changes have been noted in animal studies. The effect of mitomycin on fertility is unknown.

Pregnancy & Lactation

Pregnancy

Chemistry & Properties

2D structure
FormulaC15H18N4O5
Molecular weight334.33 g/mol
IUPAC name[(4S,6S,7R,8S)-11-amino-7-methoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate
CAS50-07-7
PubChem CID5746
InChIKeyNWIBSHFKIJFRCO-WUDYKRTCSA-N
logP-1.65 (XLogP -0.4)
Polar surface area146.89 Ų
H-bond acceptors / donors8 / 3
Drug-likeness (QED)0.41
Lipinski violations0
SMILESCO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12

Biology & Pharmacokinetics

Pharmacokinetics

BBB penetrantNo

Enzyme interactions

EnzymeRoleDetail
CYP2D6Inhibitor
CYP3A4Substrate

Transporters

BCRP (Inhibitor)BSEP (Inhibitor)MATE1 (Inhibitor)MDR1 (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)BCRP (Substrate)MDR1 (Substrate)P-gp (Substrate)

Drug–drug interactions (100+, DDInter)

Interacting drugSeverityManagement
Adalimumab major
Bacillus calmette-guerin substrain tice live antigen major
Baricitinib major
Certolizumab pegol major
Cladribine major
Clozapine major
Deferiprone major
Etanercept major
Fingolimod major
Fluorouracil major
Golimumab major
Infliximab major
Leflunomide major
Measles virus vaccine live attenuated major
Mumps virus strain B level jeryl lynn live antigen major
Natalizumab major
Ozanimod major
Rotavirus vaccine major
Rubella virus vaccine major
Samarium (153Sm) lexidronam major
Siponimod major
Smallpox (Vaccinia) Vaccine, Live major
Talimogene laherparepvec major
Teriflunomide major
Thalidomide major
Tofacitinib major
Typhoid vaccine (live) major
Upadacitinib major
Varicella Zoster Vaccine (Recombinant) major
Yellow Fever Vaccine major
Aldesleukin moderate
Alefacept moderate
Alemtuzumab moderate
Alpelisib moderate
Anakinra moderate
Anthrax vaccine moderate
Azathioprine moderate
Bendamustine moderate
Bifidobacterium longum infantis moderate
Bleomycin moderate

Showing 40 of 100+.

Registered Products (1)

BrandForm / strengthPackAgentCitizen (JOD)
Misintu Vial 20 mg 1 vial مستودع ادوية ابن رشد